Teva Pharmaceutical Industries Income After Taxes 2010-2024 | TEVA

Teva Pharmaceutical Industries annual/quarterly income after taxes history and growth rate from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
  • Teva Pharmaceutical Industries income after taxes for the quarter ending September 30, 2024 was $-0.393B, a 617.11% decline year-over-year.
  • Teva Pharmaceutical Industries income after taxes for the twelve months ending September 30, 2024 was $-1.217B, a 49.92% decline year-over-year.
  • Teva Pharmaceutical Industries annual income after taxes for 2023 was $-0.617B, a 75.52% decline from 2022.
  • Teva Pharmaceutical Industries annual income after taxes for 2022 was $-2.52B, a 663.76% decline from 2021.
  • Teva Pharmaceutical Industries annual income after taxes for 2021 was $0.447B, a 110.55% decline from 2020.
Teva Pharmaceutical Industries Annual Income After Taxes
(Millions of US $)
2023 $-617
2022 $-2,520
2021 $447
2020 $-4,238
2019 $-987
2018 $-2,401
2017 $-16,446
2016 $303
2015 $1,718
2014 $3,047
2013 $1,293
2012 $1,956
2011 $2,829
2010 $3,363
2009 $2,037
Teva Pharmaceutical Industries Quarterly Income After Taxes
(Millions of US $)
2024-09-30 $-393
2024-06-30 $-876
2024-03-31 $-415
2023-12-31 $467
2023-09-30 $76
2023-06-30 $-907
2023-03-31 $-253
2022-12-31 $-1,346
2022-09-30 $59
2022-06-30 $-260
2022-03-31 $-973
2021-12-31 $-151
2021-09-30 $306
2021-06-30 $210
2021-03-31 $82
2020-12-31 $158
2020-09-30 $-4,475
2020-06-30 $53
2020-03-31 $26
2019-12-31 $80
2019-09-30 $-303
2019-06-30 $-671
2019-03-31 $-93
2018-12-31 $-3,248
2018-09-30 $-187
2018-06-30 $-174
2018-03-31 $1,208
2017-12-31 $-11,737
2017-09-30 $613
2017-06-30 $-5,956
2017-03-31 $634
2016-12-31 $-971
2016-09-30 $408
2016-06-30 $227
2016-03-31 $639
2015-12-31 $612
2015-09-30 $120
2015-06-30 $533
2015-03-31 $453
2014-12-31 $686
2014-09-30 $868
2014-06-30 $745
2014-03-31 $748
2013-12-31 $387
2013-09-30 $713
2013-06-30 $-453
2013-03-31 $646
2012-12-31 $294
2012-09-30 $-76
2012-06-30 $871
2012-03-31 $867
2011-12-31 $524
2011-09-30 $935
2011-06-30 $590
2011-03-31 $780
2010-12-31 $780
2010-09-30 $1,052
2010-06-30 $809
2010-03-31 $722
2009-12-31 $392
2009-09-30 $652
2009-06-30 $543
2009-03-31 $450
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.384B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00